Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization
Steven Droho, Amrita Rajesh, Carla M. Cuda, Harris Perlman, Jeremy A. Lavine
Steven Droho, Amrita Rajesh, Carla M. Cuda, Harris Perlman, Jeremy A. Lavine
View: Text | PDF
Research Article Inflammation Ophthalmology

CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization

  • Text
  • PDF
Abstract

Patients with neovascular AMD (nAMD) suffer vision loss from destructive angiogenesis, termed choroidal neovascularization (CNV). Macrophages are found in CNV lesions from patients with nAMD. Additionally, Ccr2–/– mice, which lack classical monocyte–derived macrophages, show reduced CNV size. However, macrophages are highly diverse cells that can perform multiple functions. We performed single-cell RNA-Seq on immune cells from WT and Ccr2–/– eyes to uncover macrophage heterogeneity during the laser-induced CNV mouse model of nAMD. We identified 12 macrophage clusters, including Spp1+ macrophages. Spp1+ macrophages were enriched from WT lasered eyes and expressed a proangiogenic transcriptome via multiple pathways, including vascular endothelial growth factor signaling, endothelial cell sprouting, cytokine signaling, and fibrosis. Additionally, Spp1+ macrophages expressed the marker CD11c, and CD11c+ macrophages were increased by laser and present in CNV lesions. Finally, CD11c+ macrophage depletion reduced CNV size by 40%. These findings broaden our understanding of ocular macrophage heterogeneity and implicate CD11c+ macrophages as potential therapeutic targets for treatment-resistant patients with nAMD.

Authors

Steven Droho, Amrita Rajesh, Carla M. Cuda, Harris Perlman, Jeremy A. Lavine

×

Figure 8

CD11c+MaciDTR mice have reduced CNV area.

Options: View larger image (or click on image) Download as PowerPoint
CD11c+MaciDTR mice have reduced CNV area.
(A and B) IF imaging of choroi...
(A and B) IF imaging of choroidal whole mounts on Day 3 after laser injury from CD11c+MaciDTR mice. (A) In PBS-treated mice, both GFP–IBA1+ (arrowheads) and GFP+IBA1+ (white arrows) macrophages were present at laser injury sites. (B) In DT-treated mice, GFP–IBA1+ macrophages (arrowheads) and GFP+IBA1– DCs were present, but GFP+IBA1+ macrophages were depleted. (C) Schematic of experimental design for laser CNV analysis. (D and E) Representative IF image on Day 7 from a PBS-treated mouse. GFP+IBA1+ macrophages were found on Day 7 in the CD31+ CNV lesion. (G and H) Representative IF image on Day 7 from a DT-treated mouse. GFP+IBA1+ macrophages were depleted by DT and CD31+ CNV lesion area was decreased. (F and I) Quantitative analysis of CNV area between PBS- and DT-treated mice. DT treatment reduced CNV area by 40% in both per lesion (n = 54–62 per group, **P < 0.01, Mann Whitney U test) and per mouse (n = 8 per group, *P < 0.05, Mann Whitney U test) analysis. Scale bars: 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts